PEDANIOS 31/1 PND-CA



PEDANIOS 31/1 PND-CA

Medicinal Cannabis

THC/CBD:	approx. 31 % THC	
	<1%CBD	
Dominance:	Indica	
Cultivar:	Pink Diesel (PND)	
Genetics:	Pink Kush	
	Driftwood Diesel	
Origin:	Canada (CA)	
Unit:	10 g	



Strain description:

This premium strain offers a rich, combined flavor notes of gas, lavender, and spice. It is cultivated under the highest quality standards and is hand-finished and hangdried. The primary terpenes, limonene, myrcene, and caryophyllene, are thought to have analgesic, and calming properties while also offering immunostimulant, and antidepressant effects. These terpenes can also be beneficial for reducing tension and anxiety.¹ Owing to its ability to induce sleep, it is advised to use this strain in the evening.²

Plasma level of THC:



Blood plasma levels of THC after oral administration or inhalation intake [modified from source Grotenhermen 2003] ³

Inhalation: Onset after 2 - 8 min Peak effect after 10 - 30 min Duration: 2 - 3 h

Using a vaporiser is a very efficient, fast-acting, and medically recommended form of administration. The optimal temperature setting is between 175 and 210°C.

Flowers with a high THC content limit the negative effects of vaporisation, as patients need to consume less to achieve the desired effect.

PEDANIOS 31/1 PND-CA

TITRATION GUIDE

- There is currently no uniform starting dose for cannabis products nor uniform dosing information.
- The recommended starting dose should be 0.05 g of flower. For the PEDANIOS 31/1 variety, this corresponds to approx. 15.5 mg THC. Depending on effectiveness and toler-ability, the dose can be increased every 1 3 days at a maximum of 0.1 g of flower.⁴

Onset and duration of effects for inhalation and oral administration⁵

	Inha	lation	Oral	administration
Onset of Effect	()	Within seconds to minutes	Ŀ	Within 30 minutes to 2 hours
Peak Effects	Ŀ	Full effects peak within 30 minutes	Ŀ	Full effects peak within 4 hours
Duration of Effect	C	Up to 6 h <mark>ours or</mark> longer	Ŀ	Up to 12 hours or longer

Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard



Aurora Medicine UK Limited

uk@auroramedicine.com | medical@auroramedicine.com

- 1. Russo E.B. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology. 2011; 163: 1344–1364.
- Piper BJ. Mother of Berries, ACDC, or Chocolope: Examination of the Strains Used by Medical Cannabis Patients in New England. J Psychoactive Drugs. 2018 Apr-Jun;50(2):95-104.
- 3. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-60
- 4. Müller-Vahl, Kirsten & Grotenhermen, Franjo. (2017). Medizinisches cannabis: Die wichtigsten Änderungen. 114. A352- A356.
- 5. Ministry of Health HC, Health Canada. Health Effects of Cannabis. 2017.

Scanning the QR code you can be forwarded directly to the Aurora Academy UK website.

